Our results demonstrate that all six proteases, MMP3, MMP24, MMP28, CTSK, ADAM10/12, and ADAM15, showed statistically significant differences when comparing fluorescence intensity measurements from the localized OC patient group with both the metastatic OC and the healthy control groups; hence, these results indicate that this panel can be used to screen patients and diagnose ovarian cancer at an early stage. This evidence concerns the gene ADAM10 and ovarian carcinoma.